• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

3 Promising Biotech Stocks to Buy on Dips

From ANI Pharmaceuticals to T2 Biosystems, these names look good.
By BRET JENSEN
Mar 01, 2018 | 09:00 AM EST
Stocks quotes in this article: CELG, ANIP, TTOO

I continue to use the market's recent hiccups to add to some of my core positions, primarily using a simple buy/write strategy to take advantage of the larger options premiums created by Wall Street's ongoing gyrations.

Here are three good candidates for this approach that I see in the biotech space:

ANI Pharmaceuticals (ANIP)

I like to buy ANI on dips partly because the company has been mentioned as a possible buyout candidate more than once. ANI also reported this week that fourth-quarter revenues grew almost 25% year over year, while management offered solid forward guidance.

Additionally, management has done a commendable job at making small strategic acquisitions over the years while keeping a clean balance sheet. That's something that has eluded many other firms in this space. With the shares priced just over 10x forward earnings, I have no problem adding some exposure to this stock whenever Wall Street goes into "risk-off" mode.

Celgene (CELG)

This biotech stalwart fell 9% on Wednesday to close at $87.12, its lowest level in more than three years.

Celgene tanked after disclosing after the bell Tuesday that the U.S. Food and Drug Administration sent it a Refusal to File letter regarding CELG's New Drug Application for ozanimod, which aims to treat relapsing forms of multiple sclerosis. Celgene paid more than $7 billion in 2015 to buy a firm called Receptos just to acquire the rights to ozanimod.

The Refusal to File letter appears to stem from a Celgene bureaucratic snafu that certainly doesn't put management in a good light, but will probably only delay ozanimod's NDA submission, not kill it. Still, Celgene shares were already down some 30% from their recent highs even before Wednesday's selloff.

T2 Biosystems (TTOO)

This off-the-radar name is a classic "razor-and-the-razor-blade" story, where you sell your customers one device like a razor, then keep selling them an ongoing stream of supplies like razor blades.

In T2's case, the "razor" is a device called the T2Dx, which hospitals can use to diagnose bloodstream infections on-site and much faster than possible with current systems (which require sending samples to labs). The company also supplies an ongoing stream of panels that hospitals use in performing these tests.

One panel has already received government approval and is generating revenue, but T2's big potential catalyst is a new experimental panel that's designed to detect sepsis. Sepsis accounts for approximately one-third of hospital deaths, as well as 6% of overall hospital costs.

T2's new panel was 95% accurate in trials when it came to identifying the pathogens that cause this infection. And just as importantly, it can turn around test results in less than six hours vs. three days for the current system.

The new panel has already received European approval, and should garner the green light here in the United States over the next few months. That should trigger a substantial acceleration of the T2Dx installed base, as well as a big boost to company revenues.

If things fall into place, I believe TTOO could be a "multibagger" over the next few years. As such, I'm more than happy to add to my core stake whenever the market puts the shares "on sale."

(This column originally appeared Wednesday on Real Money Pro, our premium site for active traders and Wall Street professionals. Click here to get great columns like this even earlier in the trading day.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
TAGS: Investing | U.S. Equity | Healthcare | Stocks

More from Healthcare

Bearish Bets: 3 Stocks You Should Consider Shorting This Week

Bob Lang
Jul 3, 2022 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

Nuvalent Has Begun the Bottoming Process

Bruce Kamich
Jul 1, 2022 10:52 AM EDT

Let's check the charts and indicators.

CRISPR Therapeutics Has Turned the Corner

Bruce Kamich
Jul 1, 2022 8:43 AM EDT

Here's our current price target.

Johnson & Johnson Appears to Be Running Out of Steam

Bruce Kamich
Jun 22, 2022 8:25 AM EDT

The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.

Anthem's Long-Term Uptrend Is Losing Its Vigor

Bruce Kamich
Jun 22, 2022 7:40 AM EDT

The technical signals of the health benefits provider are weakening.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:34 AM EDT PAUL PRICE

    A $525,000 Vote of Confidence on Macerich (MAC)

  • 09:49 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Stop Wishing, Hoping, and Praying and Take Control...
  • 07:59 PM EDT PAUL PRICE

    Very Good Quarterly Numbers From Bassett Furniture (BSET)

    Bassett Furniture blew right through analysts es...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login